Astellas Splits Sales Emerging Growth In Russia And China, But A Late Entry To India May Soon Be Rewarded
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Japanese firm Astellas seems content pursuing emerging market growth on its own, perhaps eschewing partnering activity like its main Japanese competitors to expand in its newest markets in the BRIC countries - Brazil, Russia, India and China
You may also be interested in...
Astellas Fortifies Vesicare And Mirabegron; Looks For Organic Growth In Emerging Markets
TOKYO - Unlike its top rival Takeda Pharmaceuticals Co. Ltd., Astellas Pharma Inc. says it will primarily look for organic growth in emerging markets, although the Japanese major is not adverse to M&A if it finds the right opportunity
Astellas Fortifies Vesicare And Mirabegron; Looks For Organic Growth In Emerging Markets
TOKYO - Unlike its top rival Takeda Pharmaceuticals Co. Ltd., Astellas Pharma Inc. says it will primarily look for organic growth in emerging markets, although the Japanese major is not adverse to M&A if it finds the right opportunity
Ukraine Adopts USTR Action Plan To Improve IP Protection For Gateway To Commonwealth Of Independent States
Ukraine has agreed to adopt an action plan to strengthen the country's intellectual property regime to draw foreign investment to the second-largest emerging market in the Commonwealth of Independent States, after Russia